Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 8/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 2/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34470619 | 1.00 | P2RX7 (0.39) | P2RX7GSK3BCYP1A2CYP2D6PDE2A | |
| SCHEMBL34470594 | 0.92 | GSK3B (0.43) | P2RX7GSK3BCYP1A2CYP2D6USP30 | |
| SCHEMBL34470497 | 0.90 | P2RX7 (0.38) | P2RX7GSK3BCYP1A2CYP2D6PDE2A | |
| SCHEMBL34470460 | 0.86 | GSK3B (0.39) | P2RX7GSK3BCYP1A2CYP2D6PDE2A | |
| SCHEMBL31277984 | 0.86 | GSK3B (0.39) | P2RX7GSK3BCYP1A2CYP2D6PDE2A | |
| SCHEMBL34470593 | 0.84 | GSK3B (0.38) | P2RX7GSK3BCYP1A2CYP2D6PDE2A | |
| SCHEMBL31330662 | 0.84 | P2RX7 (0.37) | P2RX7GSK3BCYP1A2CYP2D6PDE2A | |
| SCHEMBL34470911 | 0.84 | P2RX7 (0.37) | P2RX7GSK3BCYP1A2CYP2D6PDE2A | |
| SCHEMBL34470523 | 0.83 | PIK3CA (0.38) | P2RX7GSK3BPDE2AEIF2AK4PIK3CA | |
| SCHEMBL31330604 | 0.83 | PIK3CA (0.38) | P2RX7GSK3BPDE2AEIF2AK4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720061-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246018-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-05 | — | — | WO | disclosed |